Abstract 236P
Background
This study aimed to determine the changes to body composition and the risk of adverse effects associated with chemotherapy in patients with advanced urothelial carcinoma (UC). The study also investigated whether bioimpedance analysis (BIA) is an effective method for diagnosing body composition.
Methods
We prospectively evaluated the body composition of 60 patients with locoregional muscle invasive (≥ T2 and N0-2M0) or metastatic UC between April 2021 and June 2023 at the Department of Urology, Juntendo Nerima Hospital, Tokyo, Japan. Body composition was evaluated using multifrequency BIA at baseline and during chemotherapy. The change in body composition was compared between before and during chemotherapy, and the incidence of adverse events was also determined.
Results
Twelve of the 60 patients enrolled in the study failed to complete their planned chemotherapy regimens or the chemotherapy regimen was discontinued or changed due to adverse events or problems related to underlying cancer. The patients who discontinued their treatment were significantly older and had a low muscle mass and a low skeletal muscle index. To assess the time-course changes in the body composition of the 41 patients who underwent chemotherapy, BIA was performed before each cycle. Chemotherapy-associated changes included a reduction in body weight 1.3% (±0.6%) and a decrease in fat mass 6.4% (±3.4%), while muscle mass did not change 0 .0% (±0.8%) between each cycle. Patients, aged 75 years or younger, had a more significant loss of muscle mass than older patients with a low muscle mass at baseline. (2.3% ± 1.0 % vs -1.4% ±1.1%, p=0.033).
Conclusions
BIA may be used as a method of nutrition and muscle assessment for pretreatment risk stratification of patients with advanced UC treated with chemotherapy. Moreover, our findings suggest that elderly patients with a low muscle mass may have trouble completing their chemotherapy course. Furthermore, chemotherapy is associated with changes in body composition which may lead to a loss of muscle mass in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract